| Literature DB >> 25679526 |
Lucia Monti1, Donatella Donati2, Elisabetta Menci1, Samuele Cioni1, Matteo Bellini1, Irene Grazzini1, Sara Leonini1, Paolo Galluzzi1, Sandra Bracco3, Sauro Severi4, Luca Burroni5, Alfredo Casasco6, Lucia Morbidelli7, Emiliano Santarnecchi8, Pietro Piu2.
Abstract
Literature has suggested that changes in brain flow circulation occur in patients with multiple sclerosis. In this study, digital subtraction angiography (DSA) was used to measure the absolute CCT value in MS patients and to correlate its value to age at disease onset and duration, and to expand disability status scale (EDSS). DSA assessment was performed on eighty MS patients and on a control group of forty-four age-matched patients. CCT in MS and control groups was calculated by analyzing the angiographic images. Lesion and brain volumes were calculated in a representative group of MS patients. Statistical correlations among CCT and disease duration, age at disease onset, lesion load, brain volumes and EDSS were considered. A significant difference between CCT in MS patients (mean = 4.9s; sd = 1.27 s) and control group (mean = 2.8s; sd = 0.51 s) was demonstrated. No significant statistical correlation was found between CCT and the other parameters in all MS patients. Significantly increased CCT value in MS patients suggests the presence of microvascular dysfunctions, which do not depend on clinical and MRI findings. Hemodynamic changes may not be exclusively the result of a late chronic inflammatory process.Entities:
Mesh:
Year: 2015 PMID: 25679526 PMCID: PMC4334558 DOI: 10.1371/journal.pone.0116681
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1DSA examination: anterior-posterior and lateral views of color-coded right carotid artery of control (a;b) and MS patient (b;c).
The blue colour, shown only in MS patients, demonstrates a prolonged CCT. The veins are in green and not blue in the control.
Fig 2The plots in the panels indicate the close similarity between the CCT evaluations by rater and side.
Upper panels: the CCT measurements at the right and left side ICA across the subjects in the control group evaluated by first rater (left panel) and second rater (right panel).
Fig 3The figure represents the distribution (median and IQR) of the CCT measured in seconds.
The control group showed significant lower CCT. The difference between the CCT mean in MS and CTR was 2.09 s with a confidence interval of 95% [1.77 s: 2.41 s].
Fig 4The figure displays the mean and standard deviation of the CCT (in seconds) by gender in MS patients and control group.
Clinical Data and CCT values in MS patients and Control Groups.
| MS Patients | ||||
|---|---|---|---|---|
| Characteristic | Control Subjects | Whole group | RR-MS | P-MS |
| Sample size | 44 | 80 | 45 | 35 |
| Male-to-Female ratio | 10/34 | 30/50 | 14/31 | 16/19 |
| Age yrs. | 50.7 (13.12) | 47.5 (9.05) | 45.3 (9.02) | 51.1 (9.18) |
| EDSS (IQR) | 5.25 (3.5) | 3.5 (3) | 6 (2.5) | |
| Disease duration yrs. | 13.5 (0.96) | 11.9 (1.10) | 15.1 (1,64) | |
| Age at disease onset yrs. | 35.2 (1.97) | 32.9 (1.26) | 35.2 (1.79) | |
| CCT s | 2.8 (0.51) | 4.8 (1.27) | 4.7 (0.17) | 5.1 (0.23) |
| Therapy: | ||||
| No therapy | 34 | 16 | 18 | |
| Natalizumab | 10 | 6 | 4 | |
| Glatiramer acetate | 12 | 8 | 4 | |
| Azathioprine | 5 | 2 | 3 | |
| Interferon β-1a or β-1b | 18 | 12 | 6 | |
| Other therapies | 1 | 1 | 0 | |
Data are means with standard deviations in parentheses.
* For EDSS median and IQR are instead reported. Other therapy is 4-aminopyridine.